Scarica l'app Stockscreener
2.43
1.62%
-0.04
Dopo l'orario di chiusura:
2.45
0.02
+0.82%
Precedente Chiudi:
$2.47
Aprire:
$2.49
Volume 24 ore:
1.05M
Relative Volume:
0.52
Capitalizzazione di mercato:
$235.50M
Reddito:
$20.76M
Utile/perdita netta:
$-132.49M
Rapporto P/E:
-0.9101
EPS:
-2.67
Flusso di cassa netto:
$-108.55M
1 W Prestazione:
-4.33%
1M Prestazione:
-1.62%
6M Prestazione:
+44.64%
1 anno Prestazione:
-44.52%
Intervallo 1D:
$2.4001
$2.52
Intervallo di 1 settimana:
$2.4001
$2.6899
Portata 52W:
$1.085
$4.53
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Nome
C 4 Therapeutics Inc
Settore
Industria
Telefono
(617) 231-0700
Indirizzo
490 ARSENAL WAY, WATERTOWN
Confronta CCCC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.43 | 239.38M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Iniziato | TD Cowen | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-15 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2024-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Equal-Weight |
| 2024-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Aggiornamento | Stifel | Hold → Buy |
| 2023-02-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-04-28 | Iniziato | Credit Suisse | Underperform |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-10 | Iniziato | JP Morgan | Overweight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-11-23 | Iniziato | BofA Securities | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-30 | Iniziato | Stifel | Hold |
| 2021-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-27 | Iniziato | BMO Capital Markets | Outperform |
| 2020-10-27 | Iniziato | Jefferies | Buy |
Mostra tutto
C 4 Therapeutics Inc Borsa (CCCC) Ultime notizie
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 11, 2025 - BioSpace
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Travere Therapeutics (NASDAQ: TVTX) issues 20,300 new-hire RSUs vesting over four years - Stock Titan
What analysts say about C4 Therapeutics Inc stockEx-Dividend Date Alerts & Budget Friendly Trading Alerts - earlytimes.in
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Hedge Fund Moves: Will C4 Therapeutics Inc stock remain a Wall Street favorite2025 Risk Factors & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - pharmiweb.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
TD Cowen Begins Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
TD Cowen Initiates Coverage of C4 Therapeutics (CCCC) with Buy Recommendation - Nasdaq
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (2025-12-01) - Seeking Alpha
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
C4 Therapeutics Reports Q3 2025 Financial Results - MSN
Mineralys Therapeutics reports inducement award under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
C4 Therapeutics files $400M mixed shelf offering - MSN
CCCC SEC FilingsC4 Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - Investing News Network
C4 Therapeutics (NASDAQ: CCCC) fireside chat at Evercore conference Dec. 3 2025 - Stock Titan
C4 Therapeutics Inc files for mixed shelf of up to $400 millionSEC filing - marketscreener.com
[S-3] C4 Therapeutics, Inc. Shelf Registration Statement | CCCC SEC FilingForm S-3 - Stock Titan
How C4 Therapeutics Inc. stock responds to policy changes2025 Support & Resistance & Growth Focused Investment Plans - newser.com
Using economic indicators to assess C4 Therapeutics Inc. potentialWall Street Watch & Accurate Entry/Exit Alerts - newser.com
Wells Fargo Upgrades C4 Therapeutics (CCCC) - MSN
C4 Therapeutics Inc. stock trend forecastJuly 2025 Selloffs & Detailed Earnings Play Strategies - newser.com
C 4 Therapeutics Inc Azioni (CCCC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):